4 results match your criteria: "Leeds University Teaching Hospital NHS Trust[Affiliation]"
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients.
Inflamm Bowel Dis
August 2024
Department of Gastroenterology, Cambridge University Hospital Foundation NHS Trust, Cambridge, United Kingdom.
Background: Biologic therapies are associated with increased infection risk among elderly patients with inflammatory bowel disease (IBD). However, there are few data on the safety and effectiveness of ustekinumab compared with anti-tumor necrosis factor (anti-TNF) agents in the elderly.
Methods: The study sought to compare the safety and effectiveness of ustekinumab and anti-TNF agents in elderly Crohn's disease (CD) patients.
Pregnancy Management in HIV Viral Controllers: Twenty Years of Experience.
Pathogens
April 2024
Department of Infectious Disease, Imperial College London, London W2 1PG, UK.
Article Synopsis
- The study looked at how women in the UK with HIV managed their pregnancies, especially those who can keep their virus levels very low without treatment.
- It compared pregnancies before and after 2012 when new guidelines changed how HIV was treated during pregnancy.
- Even with the changes in treatment, there were no new cases of HIV passed to babies, and the way babies were delivered varied quite a bit in recent years.
Provision of NICE-recommended varicose vein treatment in the NHS.
Br J Surg
January 2023
Academic Vascular Surgery Unit, Hull York Medical School, Hull, UK.
Background: Standardization of access to treatment and compliance with clinical guidelines are important to ensure the delivery of high-quality care to people with varicose veins. In the National Health Service (NHS) in England, commissioning of care for people with varicose veins is performed by Clinical Commissioning Groups (CCGs) and clinical guidelines have been developed by the National Institute for Health and Care Excellence (NICE CG168). The Evidence-Based Intervention (EBI) programme was introduced in the NHS with the aim of improving care quality and supporting implementation of NICE CG168.
View Article and Find Full Text PDFUstekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
Dig Dis Sci
May 2023
Department of Gastroenterology, Leeds University Teaching Hospital NHS Trust, Leeds, UK.
Background: Anti-tumour necrosis factor (anti-TNF) agents are associated with increased infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative biologics may be preferable. However, little comparative data exist on the safety and efficacy of vedolizumab and ustekinumab in elderly IBD patients.
Aims: To compare the safety and effectiveness of ustekinumab and vedolizumab in elderly Crohn's disease patients.